Literature DB >> 7888089

Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.

E C Hirsch1.   

Abstract

The cardinal neurochemical abnormality in Parkinson's disease is the decreased dopamine content in the striatum, resulting from the loss of dopaminergic neurons in the mesencephalon. Precise analysis of the dopaminergic neurons in the midbrain demonstrates, however, that this cell loss is not uniform. Some dopaminergic cell groups are more vulnerable than others. The degree of cell loss is severe in the substantia nigra pars compacta, intermediate in the ventral tegmental area and cell group A8, but nonexistent in the central gray substance. This heterogeneity provides a good paradigm for analyzing the factors implicated in this differential vulnerability. So far, the neurons that degenerate have been shown to contain neuromelanin, high amounts of iron, and no calbindin28K, and to be poorly protected against oxidative stress. By contrast, the neurons that survive in Parkinson's disease are free of neuromelanin, calbindinD28-positive, contain low amounts of iron, and are better protected against oxidative stress. The analysis of the pattern of cell loss in Parkinson's disease may thus bring new clues as to the mechanism of nerve cell death in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888089     DOI: 10.1007/BF02816113

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  35 in total

1.  Brain-derived neurotrophic factor prevents neuronal death in vivo.

Authors:  M M Hofer; Y A Barde
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

2.  Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.

Authors:  D T Dexter; C J Carter; F R Wells; F Javoy-Agid; Y Agid; A Lees; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

3.  Neuromelanin and Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neural Transm Suppl       Date:  1983

4.  Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.

Authors:  D T Dexter; F R Wells; A J Lees; F Agid; Y Agid; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-06       Impact factor: 5.372

5.  Glutathione peroxidase, glial cells and Parkinson's disease.

Authors:  P Damier; E C Hirsch; P Zhang; Y Agid; F Javoy-Agid
Journal:  Neuroscience       Date:  1993-01       Impact factor: 3.590

6.  Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.

Authors:  E C Hirsch; J P Brandel; P Galle; F Javoy-Agid; Y Agid
Journal:  J Neurochem       Date:  1991-02       Impact factor: 5.372

7.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease.

Authors:  D M Mann; P O Yates
Journal:  Mech Ageing Dev       Date:  1983-02       Impact factor: 5.432

8.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

9.  Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?

Authors:  A Kastner; E C Hirsch; O Lejeune; F Javoy-Agid; O Rascol; Y Agid
Journal:  J Neurochem       Date:  1992-09       Impact factor: 5.372

10.  EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture.

Authors:  D Casper; C Mytilineou; M Blum
Journal:  J Neurosci Res       Date:  1991-10       Impact factor: 4.164

View more
  18 in total

Review 1.  Ferritin for the clinician.

Authors:  Mary Ann Knovich; Jonathan A Storey; Lan G Coffman; Suzy V Torti; Frank M Torti
Journal:  Blood Rev       Date:  2008-10-02       Impact factor: 8.250

2.  Catecholamine oxidative products, but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice.

Authors:  L Liu; K Wakamatsu; S Ito; P R Williamson
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Dopamine uptake in the substantia nigra and striatum in the presymptomatic and early symptomatic stages in parkinsonian mice.

Authors:  G R Khakimova; E A Kozina; A Ya Sapronova; M V Ugryumov
Journal:  Dokl Biol Sci       Date:  2011-01-09

4.  A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons.

Authors:  M P Smidt; H S van Schaick; C Lanctôt; J J Tremblay; J J Cox; A A van der Kleij; G Wolterink; J Drouin; J P Burbach
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 5.  New directions in the drug treatment of Parkinson's disease.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

6.  Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.

Authors:  Michelle Healy-Stoffel; S Omar Ahmad; John A Stanford; Beth Levant
Journal:  Brain Res       Date:  2014-06-09       Impact factor: 3.252

7.  Particulate matter neurotoxicity in culture is size-dependent.

Authors:  Patricia Gillespie; Julianne Tajuba; Morton Lippmann; Lung-Chi Chen; Bellina Veronesi
Journal:  Neurotoxicology       Date:  2011-10-25       Impact factor: 4.294

Review 8.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

9.  The effect of n-acetylcysteine and deferoxamine on exercise-induced oxidative damage in striatum and hippocampus of mice.

Authors:  Aderbal S Aguiar; Talita Tuon; Fernanda S Soares; Luís Gustavo C da Rocha; Paulo César Silveira; Ricardo A Pinho
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

Review 10.  The role of DNA repair in brain related disease pathology.

Authors:  Chandrika Canugovi; Magdalena Misiak; Leslie K Ferrarelli; Deborah L Croteau; Vilhelm A Bohr
Journal:  DNA Repair (Amst)       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.